| Name | Title | Contact Details |
|---|
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
iCyt is a profitable, innovative, bioscience technology company that will contribute to its community by: delivering novel cell measurement and handling technologies that enable our clients to create important new healthcare and agriculture
NovoBiotic Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina`s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.